The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Almost 50,000 lung cancer patients have not been seen on time over the last 10 years, with thousands currently waiting more than three months to begin treatment, according to analysis of NHS data.

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...

The numbers for bowel cancer, the third-most-common type worldwide, are rising particularly fast (see chart). Compared with ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

From its beginnings as a grassroots run in Edmonton, Give a Breath 5K has grown into a powerful national force for lung cancer awareness and action. On Saturday, June 7, Canadians in Edmonton, Calgary ...

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

US FDA grants breakthrough device designation to Roche’s companion diagnostic, VENTANA TROP2 (EPR20043) RxDx Device for non-small cell lung cancer: Basel Wednesday, April 30, 20 ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

Researchers have shown that activation of the protein YAP, known to help cancer cells survive treatment, behaves very ...